GSE134029 cisplatin 3 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE134029_cisplatin_3_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE134029_cisplatin_3_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE134029_cisplatin_3_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE134029_cisplatin_3_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 1

Gene

THAP9 antisense RNA 1

Gene

MT-CO2 pseudogene 12

Gene

small nucleolar RNA host gene 12

Gene

high mobility group box 1 pseudogene 5

Gene

NSUN5 pseudogene 1

Gene

MT-ATP6 pseudogene 1

Gene

TALAM1 transcript, MALAT1 antisense RNA

Gene

hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA

Gene

MT-ND2 pseudogene 28

  • Gene

    small nucleolar RNA host gene 1


  • Gene

    THAP9 antisense RNA 1


  • Gene

    MT-CO2 pseudogene 12


  • Gene

    small nucleolar RNA host gene 12


  • Gene

    high mobility group box 1 pseudogene 5


  • Gene

    NSUN5 pseudogene 1


  • Gene

    MT-ATP6 pseudogene 1


  • Gene

    TALAM1 transcript, MALAT1 antisense RNA


  • Gene

    hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA


  • Gene

    MT-ND2 pseudogene 28

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.